DBV Technologies (DBVT) shares fell 1.5% in recent Monday trading after the company reported that full-year 2024 losses widened to $1.17 per diluted share from $0.76 a year earlier.

A single analyst polled by FactSet expected a loss of $0.98.

As expected, no revenue for the year ended Dec. 31 was reported.

As of Dec. 31, the company said it had $32.5 million in cash and cash equivalents, and expected it could fund operations through April.

The company also announced the US Food and Drug Administration agreed with its proposal to consider the safety exposure data from the Vitesse Phase 3 study for Viaskin peanut patch in children aged four to seven years for a biologics license application filing in this age group.

This expedites the submission of the application to H1 2026 and accelerates the potential launch of the product by a year if approved. The FDA's decision also eliminates the need to conduct the Comfort Children supplemental safety study, the company said.

Price: 4.54, Change: -0.07, Percent Change: -1.52